

Sarah Zohar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428993/publications.pdf>

Version: 2024-02-01

103
papers

3,334
citations

159525

30
h-index

161767

54
g-index

109
all docs

109
docs citations

109
times ranked

4104
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1298.	3.8	388
2	Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. <i>Lancet Neurology</i> , The, 2015, 14, 469-477.	4.9	208
3	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. <i>Neuro-Oncology</i> , 2006, 8, 60-66.	0.6	189
4	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010, 12, 401-408.	0.6	180
5	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 98-104.	0.5	149
6	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase III study. <i>British Journal of Haematology</i> , 2002, 119, 726-739.	1.2	119
7	Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 121-132.	0.7	112
8	The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. <i>Statistics in Medicine</i> , 2001, 20, 2827-2843.	0.8	100
9	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. <i>European Journal of Cancer</i> , 2017, 70, 133-142.	1.3	86
10	Late Morbidity After Colon Interposition for Corrosive Esophageal Injury. <i>Annals of Surgery</i> , 2010, 252, 271-280.	2.1	80
11	Surgery for Caustic Injuries of the Upper Gastrointestinal Tract. <i>Annals of Surgery</i> , 2012, 256, 994-1001.	2.1	64
12	Experimental designs for phase I and phase I/II dose-finding studies. <i>British Journal of Cancer</i> , 2006, 94, 609-613.	2.9	63
13	A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006, 95, 253-259.	2.9	55
14	Designs of drug-combination phase I trials in oncology: a systematic review of the literature. <i>Annals of Oncology</i> , 2015, 26, 669-674.	0.6	53
15	Recommendations for the design of therapeutic trials for neonatal seizures. <i>Pediatric Research</i> , 2019, 85, 943-954.	1.1	52
16	A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. <i>Pharmaceutical Statistics</i> , 2014, 13, 247-257.	0.7	50
17	Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. <i>Statistics in Medicine</i> , 2013, 32, 2728-2746.	0.8	45
18	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. <i>Biometrical Journal</i> , 2017, 59, 804-825.	0.6	41

#	ARTICLE	IF	CITATIONS
19	Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2007, 17, 1071-1083.	0.4	40
20	Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial. <i>Contemporary Clinical Trials</i> , 2008, 29, 608-616.	0.8	40
21	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.6	40
22	Esophageal replacement by allogenic aorta in a porcine model. <i>Surgery</i> , 2010, 148, 39-47.	1.0	39
23	Dose-finding approach for dose escalation with overdose control considering incomplete observations. <i>Statistics in Medicine</i> , 2011, 30, 1584-1594.	0.8	39
24	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. <i>Journal of Rheumatology</i> , 2009, 36, 1460-1463.	1.0	38
25	Anal Carcinoma in HIV-Infected Patients in the Era of Antiretroviral Therapy: A Comparative Study. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 729-735.	0.7	38
26	Competing designs for drug combination in phase I dose-finding clinical trials. <i>Statistics in Medicine</i> , 2015, 34, 1-12.	0.8	36
27	Colopharyngoplasty for the Treatment of Severe Pharyngoesophageal Caustic Injuries. <i>Annals of Surgery</i> , 2007, 246, 721-727.	2.1	35
28	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. <i>Computer Methods and Programs in Biomedicine</i> , 2003, 72, 117-125.	2.6	34
29	Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. <i>Transfusion</i> , 2007, 47, 1851-1857.	0.8	31
30	Incorporating lower grade toxicity information into dose finding designs. <i>Clinical Trials</i> , 2011, 8, 370-379.	0.7	31
31	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 44.	1.2	31
32	Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. <i>Statistical Methods in Medical Research</i> , 2018, 27, 466-479.	0.7	31
33	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 461-477.	0.6	31
34	A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent with a Molecularly Targeted Agent. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015, 64, 215-229.	0.5	30
35	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 186.	1.2	30
36	Optimal designs for estimating the most successful dose. <i>Statistics in Medicine</i> , 2006, 25, 4311-4320.	0.8	29

#	ARTICLE	IF	CITATIONS
37	Retrospective Robustness of the Continual Reassessment Method. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 1013-1025.	0.4	27
38	Determination of the optimal sample size for a clinical trial accounting for the population size. <i>Biometrical Journal</i> , 2017, 59, 609-625.	0.6	27
39	Identifying the most successful dose (MSD) in dose-finding studies in cancer. <i>Pharmaceutical Statistics</i> , 2006, 5, 187-199.	0.7	26
40	An adaptive power prior for sequential clinical trials – Application to bridging studies. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2282-2294.	0.7	25
41	Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. <i>Journal of the American Statistical Association</i> , 2014, 109, 931-943.	1.8	24
42	Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 479-485.	0.7	23
43	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. <i>Clinical Trials</i> , 2008, 5, 478-485.	0.7	23
44	Application of the Continual Reassessment Method to Dose-finding Studies in Regional Anesthesia. <i>Anesthesiology</i> , 2013, 119, 29-35.	1.3	22
45	The VAD chemotherapy regimen plus a G-CSF dose of 10% $\hat{1}$ 4g/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5% $\hat{1}$ 4g/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. <i>Bone Marrow Transplantation</i> , 2006, 37, 725-729.	1.3	21
46	Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. <i>Clinical Trials</i> , 2013, 10, 414-421.	0.7	21
47	Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. <i>Clinical Trials</i> , 2008, 5, 595-606.	0.7	20
48	Decision-theoretic designs for small trials and pilot studies: A review. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1022-1038.	0.7	20
49	The Impact of Non-Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials. <i>Clinical Cancer Research</i> , 2012, 18, 5179-5187.	3.2	19
50	Primary Hyperparathyroidism from Parathyroid Microadenoma: Specific Features and Implications for a Surgical Strategy in the Era of Minimally Invasive Parathyroidectomy. <i>Journal of the American College of Surgeons</i> , 2010, 210, 456-462.	0.2	18
51	Bumetanide for neonatal seizures – back from the cotside. <i>Nature Reviews Neurology</i> , 2015, 11, 724-724.	4.9	18
52	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1860-1877.	0.7	17
53	Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. <i>Statistics in Medicine</i> , 2011, 30, 1563-1573.	0.8	16
54	Approaches to sample size calculation for clinical trials in rare diseases. <i>Pharmaceutical Statistics</i> , 2018, 17, 214-230.	0.7	16

#	ARTICLE	IF	CITATIONS
55	Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. <i>BMJ Open</i> , 2019, 9, e022739.	0.8	15
56	Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas. <i>Pharmaceutical Statistics</i> , 2011, 10, 218-226.	0.7	14
57	Similar Outcomes After Primary and Secondary Esophagocoloplasty for Caustic Injuries. <i>Annals of Thoracic Surgery</i> , 2012, 93, 905-912.	0.7	14
58	A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology. <i>Clinical Pharmacokinetics</i> , 2009, 48, 387-395.	1.6	13
59	Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. <i>Bone Marrow Transplantation</i> , 2009, 43, 919-925.	1.3	12
60	Sensitivity of dose-finding studies to observation errors. <i>Contemporary Clinical Trials</i> , 2009, 30, 523-530.	0.8	12
61	An approach to meta-analysis of dose-finding studies. <i>Statistics in Medicine</i> , 2011, 30, 2109-2116.	0.8	12
62	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. <i>BMC Medical Research Methodology</i> , 2018, 18, 20.	1.4	12
63	Dose-finding designs for cumulative toxicities using multiple constraints. <i>Biostatistics</i> , 2019, 20, 17-29.	0.9	12
64	Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 87-101.	0.4	11
65	Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. <i>Biometrics</i> , 2022, 78, 300-312.	0.8	11
66	A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. <i>Statistics in Medicine</i> , 2012, 31, 4243-4254.	0.8	10
67	A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. <i>Haematologica</i> , 2006, 91, 550-3.	1.7	10
68	Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. <i>Clinical Trials</i> , 2013, 10, 505-514.	0.7	9
69	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. <i>PLoS ONE</i> , 2016, 11, e0166207.	1.1	9
70	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 16.	1.2	9
71	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , 2020, 29, 541-567.	0.7	8
72	Re: Dose Escalation Methods in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1732-1733.	3.0	7

#	ARTICLE	IF	CITATIONS
73	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1481-1491.	1.4	7
74	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 157, 163-177.	2.6	7
75	Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. <i>Statistical Methods in Medical Research</i> , 2019, 28, 404-418.	0.7	7
76	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 478-482.	0.6	7
77	An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. <i>Statistics in Medicine</i> , 2015, 34, 3029-3039.	0.8	6
78	Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. <i>Statistics in Medicine</i> , 2021, 40, 5096-5114.	0.8	6
79	What is the ED 95 of prilocaine for femoral nerve block using ultrasound? <i>British Journal of Anaesthesia</i> , 2013, 110, 831-836.	1.5	5
80	Bayesian variable selection based on clinical relevance weights in small sample studies—Application to colon cancer. <i>Statistics in Medicine</i> , 2019, 38, 2228-2247.	0.8	5
81	Alternate designs for conduct and analysis of phase I cancer trials. <i>Blood</i> , 2001, 98, 1275-1275.	0.6	4
82	A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. <i>Methods of Information in Medicine</i> , 2016, 55, 4-13.	0.7	4
83	A Bayesian non-inferiority approach using experts'™ margin elicitation—application to the monitoring of safety events. <i>BMC Medical Research Methodology</i> , 2019, 19, 187.	1.4	4
84	Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation. <i>Pharmaceutical Statistics</i> , 2019, 18, 198-211.	0.7	4
85	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. <i>PLoS ONE</i> , 2016, 11, e0156096.	1.1	4
86	Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials—Case Study in Bridging Data Package. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1639.	1.2	3
87	Random-effects meta-analysis of Phase I dose-finding studies using stochastic process priors. <i>Annals of Applied Statistics</i> , 2021, 15, .	0.5	3
88	The Continual Reassessment Method. , 2006, , 131-148.		2
89	dfcomb: An R-package for phase I/II trials of drug combinations. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 125, 117-133.	2.6	2
90	A Dose Finding Design for Seizure Reduction in Neonates. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 427-444.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Maximum-relevance weighted likelihood estimator: application to the continual reassessment method. <i>Statistics and Its Interface</i> , 2010, 3, 177-183.	0.2	2
92	Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. <i>Melanoma Research</i> , 2009, 19, 379-384.	0.6	1
93	Response to comments on "Competing designs for drug combination in phase I dose-finding clinical trials" by G. Yin, R. Lin and N. Wages. <i>Statistics in Medicine</i> , 2015, 34, 23-26.	0.8	1
94	Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. <i>Archives of Disease in Childhood</i> , 2018, 103, archdischild-2018-314874.	1.0	1
95	The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. <i>Pharmaceutics</i> , 2021, 13, 601.	2.0	1
96	Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. <i>Bayesian Analysis</i> , 2021, 16, .	1.6	1
97	A straightforward meta-analysis approach for oncology phase I dose-finding studies. <i>Statistics in Medicine</i> , 2022, 41, 3915-3940.	0.8	1
98	Defining Stopping Rules. , 2006, , 205-224.		0
99	Websites and Software. , 2006, , 287-306.		0
100	Dose Estimation. <i>Pharmaceutical Medicine</i> , 2008, 22, 35-40.	1.0	0
101	An adaptive model switching approach for phase I dose-finding trials. <i>Pharmaceutical Statistics</i> , 2013, 12, 225-232.	0.7	0
102	Comments on "A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies". <i>Statistics in Medicine</i> , 2016, 35, 475-478.	0.8	0
103	Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies. <i>Statistics in Biosciences</i> , 2021, 13, 142-159.	0.6	0